Vanberra Signal

Immunai

Curated by Signal

Developer of next-generation of immunomodulatory therapeutics

Overview

Developer of next-generation of immunomodulatory therapeutics. It has a properitery therapeutic engine AMICA Annotated Multiomic Immune Cell Atlas that combines multi-omic single-cell analysis with machine learning and functional genomics to accelerates drug discovery and development for immune-modulating medicines.

Key facts

Founded
2018
Headquarters
United States

Business model

Contact

Open roles

32 roles
  • Senior I / II Computational Biologist

    New York, United States · On-site · Internship

  • Data Infrastructure Team Lead

    Ramat Gan, Tel Aviv District, Israel · On-site · Internship

  • AI Infrastructure Engineer

    Ramat Gan, Tel Aviv District, Israel · On-site · Internship

+ 29 more open roles on Signal

More on Vanberra Signal

Members only

Competitors & similar companies

More Health Technology companies
  • Provider of mental health monitoring solutions for employees

    Health TechnologyCharlotte, United States
  • Digital hospital bed management tool

    Health TechnologyNew York City, United States
  • Platform offering nutritional and bodybuilding supplements

    Health TechnologyLongwood, United States

About Immunai

What does Immunai do?

Developer of next-generation of immunomodulatory therapeutics.

Where is Immunai headquartered?

Immunai is headquartered in United States.

When was Immunai founded?

Immunai was founded in 2018.

Which sector is Immunai in?

Immunai operates in Health Technology.

Who are Immunai's competitors?

Companies similar to Immunai include Mind the GAHP, CensusPro, and REPP Sports.

Is Immunai hiring?

Yes. Immunai has 32 open roles listed on Vanberra Signal.